nach oben

Medical Oncology

Erschienen in:

01.12.2012 | Case Report

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

verfasst von: H. Woopen, K. Pietzner, S. Darb-Esfahani, G. Oskay-Oezcelik, J. Sehouli

Erschienen in: Medical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Cutaneous metastasation is a very rare manifestation of ovarian cancer. We present the case of a 64-year-old woman with recurrent platinum-refractory ovarian cancer and skin metastasis. The patient was treated with intraperitoneal catumaxomab due to massive refractory malignant ascites. Clinical response of the skin metastasis was observed during the intraperitoneal treatment with catumaxomab. Even though response of extraperitoneal tumor sites can be explained with intravascular uptake and a possible vaccination effect, this phenomenon has not been reported up to this point to the best of our knowledge.

Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer. 1989;64(7):1508–13.PubMedCrossRef

Cormio G, Rossi C, Cazzolla A, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003;13(2):125–9.PubMedCrossRef

Spencer PS, Helm TN. Skin metastases in cancer patients. Cutis. 1987;39(2):119–21.PubMed

Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S. Distant metastases in epithelial ovarian carcinoma. Cancer. 1987;60(7):1561–6.PubMedCrossRef

Haughney RV, Slade RJ, Brain AN. An isolated abdominal wall metastasis of ovarian carcinoma ten years after primary surgery. Eur J Gynaecol Oncol. 2001;22(2):102–3.PubMed

Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res. 1999;5(9):2485–90.PubMed

Brownstein MH, Helwig EB. Patterns of cutaneous metastasis. Arch Dermatol. 1972;105(6):862–8.PubMedCrossRef

Yilmaz Z, Bese T, Demirkiran F, et al. Skin metastasis in ovarian carcinoma. Int J Gynecol Cancer. 2006;16(Suppl 1):414–8.PubMedCrossRef

Matsui H, Suzuka K, Yamazawa K, et al. Scalp metastasis of a serous ovarian cancer. Acta Obstet Gynecol Scand. 2002;81(6):577–8.PubMedCrossRef

10.

Traiman P, de Luca LA, Bacchi CE. An extremely large, cauliflower-type, cutaneous metastasis of ovarian cancer associated with good prognosis. Gynecol Oncol. 1994;53(2):239–41.PubMedCrossRef

11.

Schonmann R, Altaras M, Biron T, Bernheim J, Fishman A. Inflammatory skin metastases from ovarian carcinoma—a case report and review of the literature. Gynecol Oncol. 2003;90(3):670–2.PubMedCrossRef

12.

Sehouli Jalid. Symptomorientierte Therapien: Aszites. In: Multimodales Management des Ovarialkarzinoms. Bremen: UNI-MED; 2006.

13.

Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315–21.PubMedCrossRef

14.

Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17–1A antigen (Ep-CAM). J Mol Med. 1999;77(10):699–712.PubMedCrossRef

15.

Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–8.PubMedCrossRef

16.

Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64(5):415–20.PubMedCrossRef

17.

Jäger M, Schoberth A, Ruf P, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res. 2012;72(1):24–32.PubMedCrossRef

18.

Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899–905.PubMedCrossRef

19.

Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21.PubMedCrossRef

20.

Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res. 2009;29(5):1787–91.PubMed

21.

Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch K-W, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 2009;28:18.PubMedCrossRef

22.

Cheng B, Lu W, Xiaoyun W, YaXia C, Xie X. Extra-abdominal metastases from epithelial ovarian carcinoma: an analysis of 20 cases. Int J Gynecol Cancer. 2009;19(4):611–4.PubMedCrossRef

23.

Cormio G, Capotorto M, Di Vagno G, Cazzolla A, Carriero C, Selvaggi L. Skin metastases in ovarian carcinoma: a report of nine cases and a review of the literature. Gynecol Oncol. 2003;90(3):682–5.PubMedCrossRef

24.

Demirci S, Yavas F, Ozsaran Z, et al. Palliative radiotherapy for the skin metastasis of ovarian cancer: a case report and review of the literature. Med Oncol. 2010;27(3):628–31.PubMedCrossRef

25.

Patsner B, Mann WJ, Chumas J, Loesch M. Herpetiform cutaneous metastases following negative second look laparotomy for ovarian adenocarcinoma. Arch Gynecol Obstet. 1988;244(1):63–7.PubMedCrossRef

26.

Flam F, Skoog L, Wilking N. Subcutaneous metastasis from an ovarian carcinoma disappeared following tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol. 1996;64(2):225–6.PubMedCrossRef

27.

Ruf P, Kluge M, Jäger M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69(6):617–25.PubMedCrossRef

28.

Merimsky O, Chaitchik S, Inbar M. Skin metastasis of ovarian cancer: report of three cases. Tumori. 1991;77(3):268–70.PubMed

29.

Karpate SJ, Samal SL, Jain SM. Recurrent ovarian malignancy presenting as cutaneous metastasis. Indian J Dermatol. 2009;54(4):380–1.PubMedCrossRef

30.

Lalich D, Tawfik O, Chapman J, Fraga G. Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary pilomatrical neoplasm. Am J Dermatopathol. 2010;32(5):500–4.PubMedCrossRef

Titel: Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature
verfasst von: H. Woopen
K. Pietzner
S. Darb-Esfahani
G. Oskay-Oezcelik
J. Sehouli
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0285-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma

Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients

Tumor necrosis factor-α (TNF-α) stimulates the epithelial–mesenchymal transition regulator Snail in cholangiocarcinoma

Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography

Prognostic value of Twist and E-cadherin in patients with osteosarcoma

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie